Forget Rigetti Computing and Buy This Safer Quantum Stock Instead

IBM unveiled its latest quantum system, the IBM Nighthawk, featuring 120 qubits and 218 next-generation tunable couplers, and its CTO said the company expects to produce quantum computers at scale by 2029. The piece positions IBM as a lower-risk way to gain exposure to quantum computing—highlighting IBM’s diversified revenue base (tens of billions from software, consulting and hardware), its Watsonx AI and cloud consulting businesses, and noting the stock is up over 37% year-to-date—while warning that pure-play quantum names like Rigetti (up 667% over the past year but down 57% from October highs) remain high-risk and speculative.

Analysis

Market structure: Winners are diversified, cash-generative tech leaders (IBM, NVDA) that can monetize AI and buy optionality in quantum; losers are small-cap pure-play quantum stocks (RGTI) whose valuations (RGTI +667% YTD) outrun revenue and liquidity. Competitive dynamics favor incumbents with hybrid services+hardware stacks — they can price bundle solutions and out-invest startups in R&D and go-to-market. On supply/demand, demand for quantum compute remains speculative while hardware supply (cryogenics, cryo-control chips, couplers) is constrained, keeping single-name volatility high and implied vol skews elevated.

Risk assessment: Tail risks include technology dead-ends, export/regulatory controls on quantum tech, and forced dilutive capital raises for pure-plays; a capital-starved RGTI could see >50% dilution within 6–12 months. Time horizons: immediate (days) see headline-driven swings; short-term (weeks–months) expect fundraising and milestone risk; long-term (to 2029) commercialization remains optionality, not cashflow. Hidden dependencies include software/toolchain adoption, classical compute integration, and government procurement programs that could rapidly change economics.

Trade implications: Favor size in large-cap exposed names: consider 2–3% long IBM (NYSE:IBM) for durable AI + quantum optionality and 1–2% long NVDA for secular AI tailwinds, funded by trimming speculative small-cap quantum exposure. Direct short/hedge: establish a 0.5–1% short RGTI or buy 30–90 day ATM puts if it rallies >20% or fails to report progress in next quarter. Options: buy 12–18 month LEAP calls on IBM (limited cost, 1% notional) and sell 1–3 month covered calls on IBM to harvest yield; use tight stop-losses (15–20%).

Contrarian angles: The market understates the value of IBM’s recurring consulting/cloud revenue as a de-risked way to own quantum optionality — IBM could compound at mid-single digits while delivering binary upside from quantum milestones by 2029. Conversely, the pure-play selloff could overshoot if a capital event forces liquidation — that creates a tactical buy-if-cheap opportunity (e.g., RGTI down >70% from highs or on post-dilution price collapse). Watch for government funding announcements and quarterly quantum KPIs as triggers that will re-rate winners and losers quickly.

Key Decisions for Investors

• Establish a 2–3% long position in IBM (NYSE:IBM) over the next 4–8 weeks; scale in on any pullback ≥5% from current levels and allocate up to an additional 1% into 12–18 month LEAP calls (limited-cost optionality) to capture quantum upside to 2029.
• Reduce speculative small-cap quantum exposure by 50% immediately; redeploy proceeds into NVDA (1–2% position) for AI secular exposure and into cash to fund tactical hedges against dilution risk in pure-plays.
• Initiate a 0.5–1% short position in RGTI or purchase 30–90 day ATM puts if RGTI rallies >20% from today or fails to announce clear roadmap/funding in the next quarter; set stop-loss at 20% adverse move and cover if RGTI falls >40%.
• Sell 1–3 month covered calls on 25–50% of IBM holdings to generate 2–4% annualized yield while retaining long exposure; roll or buy back if implied vol falls >30% or ahead of major IBM quantum/AI catalysts.
• Monitor catalysts: IBM Nighthawk updates, Rigetti funding/milestones, and government quantum funding announcements over the next 90 days — treat any positive national procurement news as a trigger to add 0.5–1% to IBM/NVDA exposure and any forced dilutive financing as a trigger to add to beaten-down pure-plays only after >70% drawdown.